

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|  |   |  |  |
|--|---|--|--|
| <b>Licensee</b><br><br>1. Hurley Medical Center<br>Department of Radiology<br><br>2. One Hurley Plaza<br>Flint, MI 48503 |   | In accordance with letter dated<br>October 17, 2017.                           | 4. Expiration Date: March 31, 2026   |
|  |   |  | 5. Docket No.: 030-01993<br>Reference No.:   |
|  |   | 3. License number: 21-00338-02 is amended in its entirety to read as follows:  |  |
| 6. Byproduct, source, and/or special nuclear material  | 7. Chemical and/or physical form                  | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use  |
| A. Any byproduct material permitted by 10 CFR 35.100   | A. Any  | A. As Needed   | A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.   |
| B. Any byproduct material permitted by 10 CFR 35.200   | B. Any  | B. As Needed   | B. For use in imaging and localization studies permitted by 10 CFR 35.200.         |
| C. Any byproduct material permitted by 10 CFR 35.300   | C. Any  | C. 1 curie total   | C. For any use permitted by 10 CFR 35.300.   |
| D. Yttrium-90 permitted by 10 CFR 35.1000  | D. Microspheres (MDS Nordion, Model TheraSpheres) | D. 500 millicuries total   | D. For medical use as permitted by 35.1000 in a TheraSpheres dose delivery system. |

---

 CONDITIONS

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-00338-02Docket or Reference Number  
030-01993

Amendment No. 139


10. Licensed material may be used or stored at the licensee's facilities located at: One Hurley Plaza, Flint, Michigan, 48503
11. The Radiation Safety Officer (RSO) for this license is Anish Bansal, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u>  |
|-------------------------|--|
| P. B. Lauber, M.D.      | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| M. Rao Tummala, M.D.    | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 36 millicuries) |
| Apparao Mukkamala, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| Ahmed M. Akl, M.D.      | 10 CFR 35.300  |
| Anant Patel, M.D.       | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; (limited to the oral administration of sodium iodide I-131)   |
| Gurkan Ege, M.D.        | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; (limited to the oral administration of sodium iodide I-131)   |
| Gagandeep Singh, M.D.   | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; (limited to the oral administration of sodium iodide I-131)   |
| Ambreen Stattar, M.D.   | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; and 10 CFR 35.1000 (limited to yttrium-90 TheraSpheres)   |
| Anish Bansal, M.D.      | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300; and 10 CFR 35.1000 (limited to yttrium-90 TheraSpheres)   |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-00338-02Docket or Reference Number  
030-01993

Amendment No. 139

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 27, 2015 (ML15302A335)
- B. Letter dated February 29, 2016 (ML16062A111)
- C. Letter dated June 14, 2017 (ML17172A088)
- D. Letter dated October 17, 2017 (ML17291A400)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Colleen Carol Casey  
Colleen Carol Casey  
Region 3Date: January 5, 2018